// App-Quantinova.ai

OP0250 (2022) : BREAKTHROUGH INFECTIONS AND PREDICTING SEVERE COVID OUTCOMES DURING RITUXIMAB THERAPY IN AUTOIMMUNE RHEUMATIC DISEASES

Researchers

Presenter

  • M. Y. Md. Yusof

Principal Investigators

  • J. Arnold

  • B. Saleem

  • C. Vandevelde

  • S. Dass

  • S. Savic

  • E. Vital

  • P. Emery

Medical Centers

  • University of Leeds, Leeds Institue of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom

  • Leeds Teaching Hospitals NHS Trust and NIHR Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom

  • Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

Disease

  • Coronavirus disease

Biomarkers

  • N/A

Drug/Treatment

  • Rituximab

Outcome

  • N/A

Study Design

  • Observational

  • Cohort

  • Single Center

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • Novartis

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved